Ionis Pharmaceuticals (IONS) Short term Debt (2009 - 2026)

Ionis Pharmaceuticals' Short term Debt history runs 17 years deep, the most recent figure standing at $432.5 million for Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $432.5 million; the TTM figure through Mar 2026 stood at $432.5 million (changed N/A YoY), while the FY2025 annual figure was $431.9 million, changed N/A from the prior year.
• Short term Debt for Q1 2026 stood at $432.5 million, roughly flat from $431.9 million in the prior quarter.
• The five-year high for Short term Debt was $630.9 million in Q3 2025, with the low at $4.2 million in Q1 2022.
• The 5-year median for Short term Debt is $44.4 million (2024), against an average of $210.6 million.
• The sharpest annual moves came in 2022 and 2025: Short term Debt slumped 93.2% in 2022, then jumped 1318.83% in 2025.
• Ionis Pharmaceuticals' Short term Debt stood at $5.0 million in 2022, then surged by 791.99% to $44.3 million in 2023, then climbed by 0.3% to $44.5 million in 2024, then soared by 871.39% to $431.9 million in 2025, then grew by 0.13% to $432.5 million in 2026.
• Business Quant data shows IONS's Short term Debt at $432.5 million in Q1 2026, $431.9 million in Q4 2025, and $630.9 million in Q3 2025.